Refine
Has Fulltext
- yes (1)
Is part of the Bibliography
- yes (1)
Year of publication
- 2007 (1)
Document Type
- Doctoral Thesis (1) (remove)
Language
- English (1) (remove)
Keywords
- Translation (1) (remove)
Institute
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an autosomal recessive neuronal disorder in infants. The disease is marked by early onset of respiratory distress and predominantly distal muscle weakness, as consequences of diaphragmatic paralysis and progressive degeneration of  motor neurons in the spinal cord, respectively. Genetically, SMARD1 is caused by mutations in the single gene encoding Immunoglobulin µ-Binding Protein 2 (IGHMBP2). Despite the tissue specific degeneration observed in SMARD1 patients, the disease gene product IGHMBP2 is ubiquitously expressed in human and mouse tissues. Therefore, SMARD1 appears to be a motor neuron disease caused by the malfunction of a “housekeeping” protein, rather than a neuron specific factor. IGHMBP2 harbors an N-terminal DEXDc-type helicase/ATPase domain and has been classified as a member of the Superfamily 1 (SF1) of helicases. This protein has been assigned to various cellular activities such as DNA replication, pre-mRNA splicing and transcription. However its precise function in either process has remained elusive. The study presented here aimed at the enzymatic characterization of IGHMBP2, the identification of a specific cellular process to which IGHMBP2 is connected and the role of this factor in the pathophysiology of SMARD1. As a first step toward this end, a two-step purification strategy was established, which enabled the large-scale purification of properly folded and enzymatically active IGHMBP2. In vitro enzymatic studies using this recombinant protein defined IGHMBP2 as an ATP-dependent helicase that catalyzes unwinding of duplices composed of either DNA or RNA in a 5’→3’ direction. In contrast to previous reports, indirect immunofluorescence studies revealed a predominantly cytoplasmic localization of IGHMBP2. Size-fractionation studies and affinity-purification experiments further showed that IGHMBP2 is part of an RNase-sensitive macromolecular complex, which was identified as the ribosome. Interestingly, IGHMBP2 was abundantly detected in both subunits as well as to 80S ribosomes but only in small amounts in actively translating polysomes. These data strongly point to a role of IGHMBP2 in ribosomes-associated gene regulation control, such as in mRNA stabilization or mRNA translation. However, its precise function in those pathways remains to be identified. The biochemical and enzymatic characterization of IGHMBP2 allowed for the first time insights into the pathomechanism of SMARD1. SMARD1-causing pathogenic IGHMBP2 variants were investigated for their enzymatic activities and interaction with ribosomal subunits. Interestingly, among all missense mutations that have been tested thus far, none obstructs association with ribosomal subunits. However, these mutants exhibit specific defects in either the ATPase or RNA helicase activity or both. The data suggest that defects in the enzymatic activity of IGHMBP2 directly correlate with the pathogenesis of SMARD1. Furthermore, these data also raise the possibility that the disease SMARD1 is caused by alterations in the cellular translation machinery.